A proposed clinical test for monitoring fluoropyrimidine therapy: Detection and stability of thymidylate synthase ternary complexes

Cancer Biology and Therapy

Volumn 5, Issue 8, 2006, Pages 923-927

  Brody, Jonathan R ^a   Gallmeier, Eike ^a   Yoshimura, Kiyoshi ^a   Hucl, Tomas ^a   Kulesza, Peter ^a   Canto, Marcia I ^a   Hruban, Ralph H ^a   Schulick, Richard D ^a   Kern, Scott E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b 451 CRB ^*  (United States)

Author keywords

5 fluorouracil; Antifolates; Leucovorin; Ternary complex; Thymidylate synthase

Indexed keywords

AMINOPTERIN; FLOXURIDINE DERIVATIVE; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; PEMETREXED; RALTITREXED; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; SACCHAROMYCES CEREVISIAE;

EID: 33751093171     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.8.2976     Document Type: Article

References (37)

1. Santi DV, McHenry CS. 5-Fluoro-2′-deoxyuridylate: Covalent complex with thymidylate synthetase. Proc Natl Acad Sci USA 1972; 69:1855-7.
2. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005; 12:191-202.
3. Johnston PG, Liang CM, Henry S, Chabner BA, Allegra CJ. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue. Cancer Res 1991; 51:6668-76.
4. Drake JC, Allegra CJ, Johnston PG. Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106. Anticancer Drugs 1993; 4:431-5.
5. Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 1993; 43:527-33.
6. Langenbach RJ, Danenberg PV, Heidelberger C. Thymidylate synthetase: Mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 1972; 48:1565-71.
7. Danenberg PV, Langenbach RJ, Heidelberger C. Structures of reversible and irreversible complexes of thymidylate synthetase and fluorinated pyrimidine nucleotides. Biochemistry 1974; 13:926-33.
8. Moran RG, Spears CP, Heidelberger C. Biochemical determinants of tumor sensitivity to 5-fluorouracil: Ultrasensitive methods for the determination of 5-fluoro-2′-deoxyuridylate, 2′-deoxyuridylate, and thymidylate synthetase. Proc Natl Acad Sci USA 1979; 76:1456-60.
9. Spears CP, Gustavsson BG, Mitchell MS, Spicer D, Berne M, Bernstein L, Danenberg PV. Thymidylate synthetase inhibition in malignant tumors and normal liver of patients given intravenous 5-fluorouracil. Cancer Res 1984; 44:4144-50.
10. Spears CP, Gustavsson BG, Berne M, Frosing R, Bernstein L, Hayes AA. Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 1988; 48:5894-900.
11. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7:890-9.
12. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 1982; 42:450-6.
13. Fukushima M, Fujioka A, Uchida J, Nakagawa F, Takechi T. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001; 37:1681-7.
14. Jakob C, Liersch T, Meyer W, Baretton GB, Hausler P, Schwabe W, Becker H, Aust DE. Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): Correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemoradiotherapy. Am J Surg Pathol 2005; 29:1304-9.
15. Santini D, Vincenzi B, Perrone G, Rabitti C, Borzomati D, Caricato M, La Cesa A, Grilli C, Verzi A, Coppola R, Tonini G. Thymidylate synthase expression in normal colonic mucosa: A predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy. Oncology 2004; 67:135-142.
16. Tahara M, Ochiai A, Fujimoto J, Boku N, Yasui W, Ohtsu A, Tahara E, Yoshida S. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 2004; 11:9-15.
17. Ullman B, Lee M, Martin Jr DW, Santi DV. Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 1978; 75:980-3.
18. Cadman E, Heimer R, Benz C. The influence of methotrexate pretreatment on 5-fluorouracil metabolism in L1210 cells. J Biol Chem 1981; 256:1695-704.
19. Bowen D, White JC, Goldman ID. A basis for fluoropyrimidine-induced antagonism to methotrexate in Ehrlich ascites tumor cells in vitro. Cancer Res 1978; 38:219-22.
20. Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, Gespach C. Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Int J Oncol 2002; 21:361-7.
21. Fernandes DJ, Bertino JR. 5-fluorouracil-methotrexate synergy: Enhancement of 5-fluorodeoxyridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc Natl Acad Sci USA 1980; 77:5663-7.
22. Bertino JR. Modulation of fluorouracil by methotrexate. J Clin Oncol 1991; 9:1511-2.
23. Sobrero A, Romanini A, Russello O, Nicolin A, Rosso R, Bertino JR. Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: Implications for the mechanism of this interaction. Eur J Cancer Clin Oncol 1989; 25:977-82.
24. Bertino JR, Mini E, Fernandes DJ. Sequential methotrexate and 5-fluorouracil: Mechanisms of synergy. Semin Oncol 1983; 10:2-5.
25. Cadman E, Heimer R, Davis L. Enhanced 5-fluorouracil nucleotide formation after methotrexate administration: Explanation for drug synergism. Science 1979; 205:1135-7.
26. Sirotnak FM. Folate antagonists as therapeutic agents. New York: Academic Press, 1984.
27. Wu Q, Dolnick BJ. Detection of thymidylate synthase modulators by a novel screening assay. Mol Pharmacol 2003; 63:167-73.
28. Myers CE, Young RC, Chabner BA. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest 1975; 56:1231-8.
29. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974; 13:471-81.
30. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11:5-14.
31. Walling J. From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates. Invest New Drugs 2006; 24:37-77.
32. Bertino JR, Sawicki WL, Lindquist CA, Gupta VS. Schedule-dependent antitumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977; 37:327-8.
33. Reyes P. The synthesis of 5-fluorouridine 5′-phosphate by a pyrimidine phosphoribosyltransferase of mammalian origin. I. Some properties of the enzyme from P1534J mouse leukemic cells. Biochemistry 1969; 8:2057-62.
34. Leyland-Jones B, O'Dwyer PJ. Biochemical modulation: Application of laboratory models to the clinic. Cancer Treat Rep 1986; 70:219-29.
35. Dolnick BJ, Cheng YC. Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem 1978; 253:3563-7.
36. Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′- deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 1989; 38:335-42.
37. Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan A, Forastiere A, Brahmer J, Clark DP, Hidalgo M. C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 2006; 66:2385-90.